FDA
-
-
-
-
-
-
-
Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
-
-
-
-
-
-
-
Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
-
-
-
-
-
-
329,074 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

